A fairly frequent problem is infection by the urogenital protozoan Trichomonas vaginalis. It is perhaps the most common clinically recognized sexually transmitted disease in the United States, with about 2.5 million new cases occurring annually. Approximately 180 million new cases occur each year worldwide . The infection has a continuous endemic source, for as many as half of the female carriers are totally asymptomatic. Newer treatments have greatly improved therapy for this disease, but diagnosis and the detection of carriers remain significant challenges. Symptomatic or asymptomatic urethritis or vaginitis due to T. vaginalis is the usual scenario. The spectrum of symptoms associated with this disease is wide. Ultimately, the diagnosis is established by identifying the causative organisms.
KeywordsEstrogen Assure Candida Metronidazole Schiff
Unable to display preview. Download preview PDF.
- 3.Sweet RL: Importance of differential diagnosis in acute vaginitis. Am J Obstet Gynecol 152:7:921–923; 1985.Google Scholar
- 6.Alderete JF, Guillermo EG: Specific nature of Trichomonas vaginalis parasitism of host cell surfaces. Infect Immunol 50:701–703, 1985.Google Scholar
- 8.Wherton A, Honigberg BM: Structure of trichomonads as revealed by scanning electron microscopy. J Protozool 26:56–62, 1979.Google Scholar
- 10.Connelly RJ, Torian BE, Stibbs HH: Identification of a surface antigen of Trichomonas vaginalis. Infect Immunol 49:270–214, 1985.Google Scholar
- 14.Lossick JG: Treatment of Trichomonas vaginalis infections. Infect Dis 4(Suppl.):801–818, 1987.Google Scholar
- 15.U.S. Department of Health and Human Services: STD Treatment Guidelines 1985. Washington, D.C.: U.S. Government Printing Office, 1985.Google Scholar